TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, August 21 for the fiscal quarter ended June 30, 2015. The Corporation’s unaudited Q1 2016 financial statements and MD&A are available on SEDAR.
Antibe is performing validation studies in an effort to gain a better understanding of why the higher doses of ATB-346 caused damage to liver cells in some subjects in the Phase 1 clinical trial. Two potential mechanisms are being investigated.
Help employers find you! Check out all the jobs and post your resume.
